Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Recently Diagnosed

PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

114

Participants

Timeline

Start Date

February 1, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

April 30, 2026

Conditions

Polymyalgia Rheumatica

Interventions

DRUG

Rituximab

Rituximab 1000mg in 250ml NaCl 0.9% intravenously with usual premedication

DRUG

Placebo

Placebo in 250ml NaCl 0.9% intravenously with usual premedication

Trial Locations (1)

Sint Maartensklineik, Ubbergen

All Listed Sponsors

collaborator

Dutch Arthritis Association

INDUSTRY

collaborator

ZonMw: The Netherlands Organisation for Health Research and Development

OTHER

lead

Sint Maartenskliniek

OTHER